Japan considers stricter oversight as private regenerative therapies spark safety concerns
Patient deaths and infections linked to privately paid stem-cell and exosome treatments have led Japan's health ministry to explore tighter regulation of regenerative medicine.
Japan's private clinics are expanding the use of regenerative medicine, including stem-cell and newly popular exosome therapies, often marketed with anti-aging or cancer-fighting claims. Under the existing safety law, treatments are classified into three risk tiers, and the number of approved plans has grown from 2,570 in 2015 to 6,703 in 2025, largely for autologous stem-cell or somatic-cell procedures. However, incidents such as two 2024 hospitalisations from contaminated immune-cell infusions and deaths in 2025-2026 after fat-derived cell injections have raised alarm.
The Health, Labor and Welfare Ministry has issued emergency orders to halt unsafe practices, yet some clinics have closed only to relocate elsewhere. A ministerial working group has voiced concerns that expert-panel reviews are becoming perfunctory and that exosome products fall outside current legislation, prompting a planned report on assessment, patient disclosure, and adverse-event reporting due by March.
Why it matters
Unsafe regenerative treatments risk patient health and may force Japan to overhaul its medical-technology regulatory framework.
In this story
